Age-related Macular Degeneration (AMD) Integrative Biology Initiative: Discovery of AMD Pathobiology using Patient-Derived Induced Pluripotent Stem Cell (iPSC)-derived Retinal Pigment Epithelium (RPE) (U01 Clinical
The summary for the Age-related Macular Degeneration (AMD) Integrative Biology Initiative: Discovery of AMD Pathobiology using Patient-Derived Induced Pluripotent Stem Cell (iPSC)-derived Retinal Pigment Epithelium (RPE) (U01 Clinical grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Age-related Macular Degeneration (AMD) Integrative Biology Initiative: Discovery of AMD Pathobiology using Patient-Derived Induced Pluripotent Stem Cell (iPSC)-derived Retinal Pigment Epithelium (RPE) (U01 Clinical: This Funding Opportunity Announcement (FOA) aims to support collaborative studies of a unique resource of patient-derived induced pluripotent stem cell (iPSC) lines generated by the NEI age-related macular degeneration (AMD) Integrative Biology Initiative. This resource also includes clinical, genomic, and imaging data from the patients from which these cells were derived, and a set of isogenic control cell lines in which the risk allele(s) have been corrected. These cell lines and clinical data are from patients with AMD carrying high prevalence risk alleles selected from the Age-Related Eye Disease Study 2 (AREDS2). The goal of this FOA is to determine if these iPSC-derived cell lines can be used to discover the underlying pathophysiology of AMD. Collaborative effort is highly encouraged with investigators bringing in the needed areas of expertise for successful projects.
| Federal Grant Title: | Age-related Macular Degeneration (AMD) Integrative Biology Initiative: Discovery of AMD Pathobiology using Patient-Derived Induced Pluripotent Stem Cell (iPSC)-derived Retinal Pigment Epithelium (RPE) (U01 Clinical |
| Federal Agency Name: | National Institutes of Health (HHS-NIH11) |
| Grant Categories: | Health |
| Type of Opportunity: | Discretionary |
| Funding Opportunity Number: | RFA-EY-21-002 |
| Type of Funding: | Cooperative Agreement |
| CFDA Numbers: | 93.867 |
| CFDA Descriptions: | Information not provided |
| Current Application Deadline: | February 17th, 2022 |
| Original Application Deadline: | February 17th, 2022 |
| Posted Date: | November 17th, 2021 |
| Creation Date: | November 17th, 2021 |
| Archive Date: | March 25th, 2022 |
| Total Program Funding: | |
| Maximum Federal Grant Award: | $250,000 |
| Minimum Federal Grant Award: | |
| Expected Number of Awards: | |
| Cost Sharing or Matching: | No |
| Last Updated: | January 24th, 2022 |
- Applicants Eligible for this Grant
- State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
- Link to Full Grant Announcement
- http://grants.nih.gov/grants/guide/rfa-files/RFA-EY-21-002.html
- Grant Announcement Contact
- NIH OER Webmaster
[email protected]
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires. - Similar Government Grants
- • NEI Small Business Innovation Research (SBIR) Cooperative Agreement for Early-Stage Clinic...
- • NEI Translational Research Program for Therapeutics (R33 Clinical Trial Not Allowed)
- • NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)
- • NEI Institutional Mentored Physician Scientist Award (K12 Clinical Trial Optional)
- • NEI Collaborative Clinical Vision Research Project: Coordinating Center Grant (UG1 Clinica...
- • Nei Career Transition Award (K22)
- • NEI Translational Research Program On Therapy For Visual Disorders
- • NEI Clinical Study Planning Grant Program (R34)
- More Grants from the National Institutes of Health
- • Hazardous Materials Worker Health and Safety Training (U45 Clinical Trials Not Allowed)
- • Lasker Clinical Research Scholars Program (Si2/R00 Clinical Trial Optional)
- • Type 1 Diabetes TrialNet Clinical Network Hub (U01 Clinical Trial Not Allowed)
- • Advancing HIV service delivery through pharmacies and pharmacists (R21 Clinical Trial Opti...
- • Advancing HIV service delivery through pharmacies and pharmacists (R01 Clinical Trial Opti...